Biolase Technology, Inc. (BIOL) Misses Q2 EPS by 9c

Biolase Technology, Inc. (NASDAQ: BIOL) reported Q2 EPS of ($0.17), $0.09 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $10.2 million versus the consensus estimate of $12.97 million.

For earnings history and earnings-related data on Biolase Technology, Inc. (BIOL) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Jefferies Downgrades Pediatrix Medical Group (MD) to Hold
• 374Water Inc (SCWO) Misses Q2 EPS by 15c